share_log

Is Micro-Tech (Nanjing) Co.,Ltd's (SHSE:688029) Recent Stock Performance Tethered To Its Strong Fundamentals?

Is Micro-Tech (Nanjing) Co.,Ltd's (SHSE:688029) Recent Stock Performance Tethered To Its Strong Fundamentals?

艾斯微科技(南京)有限公司,Ltd(上海證券交易所代碼:688029)最近的股票表現與其強勁的基本面息息相關?
Simply Wall St ·  05/21 19:54

Micro-Tech (Nanjing)Ltd's (SHSE:688029) stock is up by a considerable 14% over the past month. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. Particularly, we will be paying attention to Micro-Tech (Nanjing)Ltd's ROE today.

南微醫學(南京)有限公司的(SHSE:688029)股價在過去一個月內上漲了相當可觀的14%。鑑於公司的出色表現,我們決定更詳細地研究其財務指標,因爲公司的長期財務狀況通常決定市場結果。特別是今天我們將關注南微醫學(南京)有限公司的roe。

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

股東權益回報率(ROE)是測試公司如何有效地增加其價值並管理投資者資金的指標。簡而言之,它用於評估公司相對於股本資本的盈利能力。

How Do You Calculate Return On Equity?

怎樣計算ROE?

Return on equity can be calculated by using the formula:

股東權益報酬率可以使用以下公式計算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

淨資產收益率 = 淨利潤(從持續經營中獲得)÷ 股東權益

So, based on the above formula, the ROE for Micro-Tech (Nanjing)Ltd is:

因此,基於上述公式,南微醫學(南京)有限公司的roe爲:

14% = CN¥539m ÷ CN¥3.8b (Based on the trailing twelve months to March 2024).

14% = CN¥53900萬 ÷ CN¥38億(基於2024年3月以前的過去12個月)。

The 'return' is the amount earned after tax over the last twelve months. Another way to think of that is that for every CN¥1 worth of equity, the company was able to earn CN¥0.14 in profit.

“回報”是指過去十二個月的稅後收益額。換句話說,對於每一元人民幣的權益,公司能夠賺取0.14元人民幣的利潤。

What Is The Relationship Between ROE And Earnings Growth?

既然我們已經確定ROE是一種有效的利潤生成標準,用於評估公司未來的盈利能力,我們現在需要評估公司“保留”爲未來增長而重新投資的利潤多少,這使我們對公司的增長潛力有了一個了解。一般而言,在其他條件相等的情況下,ROE和利潤留存高的公司,增長率比沒有這些屬性的公司要高。

So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

到目前爲止,我們已經了解了roe是公司盈利能力的一種衡量標準。根據公司重新投資或“保留”的利潤數量和效率,我們可以評估公司的盈利增長潛力。假設其他所有因素保持不變,roe和保留的利潤越高,相對於不一定具有這些特徵的公司,公司的增長率就越高。

A Side By Side comparison of Micro-Tech (Nanjing)Ltd's Earnings Growth And 14% ROE

南微醫學(南京)有限公司盈利增長和14% roe的並排比較

To begin with, Micro-Tech (Nanjing)Ltd seems to have a respectable ROE. Further, the company's ROE compares quite favorably to the industry average of 7.4%. This probably laid the ground for Micro-Tech (Nanjing)Ltd's moderate 16% net income growth seen over the past five years.

首先,南微醫學(南京)有限公司似乎擁有一個令人尊重的roe。此外,該公司的roe與行業板塊平均水平相比非常有優勢。這很可能爲南微醫學(南京)有限公司過去五年實現的中等規模的16%淨利潤增長奠定了基礎。

Next, on comparing with the industry net income growth, we found that Micro-Tech (Nanjing)Ltd's growth is quite high when compared to the industry average growth of 6.9% in the same period, which is great to see.

接下來,通過與行業淨利潤增長進行比較,我們發現南微醫學(南京)有限公司在同一時期相比行業平均增長率6.9%的增速非常高,這是一個好兆頭。

past-earnings-growth
SHSE:688029 Past Earnings Growth May 21st 2024
SHSE:688029過去的盈利增長情況

Earnings growth is a huge factor in stock valuation. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. Is Micro-Tech (Nanjing)Ltd fairly valued compared to other companies? These 3 valuation measures might help you decide.

盈利增長是股票估值的一個重要因素。投資者需要判斷的是預期的盈利增長或其缺乏是否已經反映在股價中,這有助於他們判斷股票是否處於光明或黯淡的未來。南微醫學(南京)有限公司與其他公司相比是否定價合理?這3個估值指標也許能幫助你做決定。

Is Micro-Tech (Nanjing)Ltd Making Efficient Use Of Its Profits?

南微醫學(南京)有限公司是否有效利用了其利潤?

Micro-Tech (Nanjing)Ltd has a healthy combination of a moderate three-year median payout ratio of 31% (or a retention ratio of 69%) and a respectable amount of growth in earnings as we saw above, meaning that the company has been making efficient use of its profits.

南微醫學(南京)有限公司具有3年中位數股利支付率爲31%(或留存比率爲69%)和適量的盈利增長,正如我們上面所看到的,這意味着該公司一直在有效利用其利潤。

Moreover, Micro-Tech (Nanjing)Ltd is determined to keep sharing its profits with shareholders which we infer from its long history of four years of paying a dividend.

此外,南微醫學(南京)有限公司決定繼續分紅,這可以從其連續四年支付股息的長期歷史中推斷出來。

Summary

總的來說,我們對偉明環保的表現非常滿意。具體而言,我們喜歡公司以高回報率再投資了其利潤的很大一部分。當然,這導致公司的收益大幅增長。但是,最新的行業分析師預測表明,該公司的收益預計將加速增長。

Overall, we are quite pleased with Micro-Tech (Nanjing)Ltd's performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

總的來說,我們對南微醫學(南京)有限公司的表現相當滿意。具體而言,我們喜歡該公司正在以高回報率重新投資其巨額利潤。當然,這導致公司的收益增長顯著。因此,最新的分析師預測顯示,公司將繼續看到其收益擴張,欲了解關於該公司最新的分析師預測的更多信息,請查看此分析師預測可視化工具。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論